choose content

Choose content

Enter keywords to create a newsletter
create account

Create account

Enter your registration information
set preferences

Set preferences

Set up your newsletter name, delivery and time zone preferences
Hint: Enter different keywords to generate new results.

Now you can:

  1. Search the news index.
  2. Browse more than 1 million newsletters by category.
  3. Use preset newsletters:

Avastin Newsletter
  • FDA’s Published CRLs Deliver Insight Into the Drug Approval Process 16 Jul 2025 17:44 GMT

    … drug developer perform an additional adequate, well-controlled, randomized clinical trial … (Avastin) … Pharmaceuticals, Inc. and Shilpa Medicare … Pharmaceuticals receives FDA approval for Lymphir (denileukin diftitox-cxdl) immunotherapy for the treatment …

  • Survey data shows trends for AMD and DME treatments and future prospects 16 Jul 2025 00:03 GMT

    … the competitive and complex treatment landscape for neovascular age … expectations shaped by emerging treatments and payer influence. Findings … second line product, after Avastin, due to its long … begin to require biosimilar trials before branded biologic access. …

  • FDA Receives sNDA for Relacorilant in Platinum-Resistant Ovarian Cancer 15 Jul 2025 21:14 GMT

    … has been submitted to the FDA, according to a news release … phase 2 trials: the completed phase 2 CORT125134-552 trial (NCT03776812), which … bevacizumab (Avastin). Corcept submits new drug application for relacorilant as a treatment for …

  • Emi-Le ADC Shows Early Promise Across B7-H4–Expressing Tumors 18 Jul 2025 15:04 GMT

    … novel B7-H4–targeted antibody-drug conjugate (ADC), demonstrated early … patients are still ongoing on treatment. What were the most … a proteinuria like a bevacizumab [Avastin] that you think about, … . Are there any other trials that are evaluating the B7 …

  • Avutometinib/Defactinib Display Safety, Efficacy in Ovarian Cancer Subtype 15 Jul 2025 21:16 GMT

    … treated with prior bevacizumab (Avastin) vs 43% (95% CI … John Hayslip, MD, chief medical officer at Verastem Oncology, … RAMP 301 (NCT06072781) trial of the combination in … acneiform (4%). Additionally, treatment-related increased creatine phosphokinase (CPK …

  • PFS Improves With TACE-Based Regimen in Unresectable Liver Cancer 13 Jul 2025 14:00 GMT

    … (Tecentriq) and bevacizumab (Avastin), according to a presentation … , Xi’an International Medical Center Hospital, in China … of AEs related to treatment. Treatment-related grade 3 … research grants from Shanghai Roche Pharmaceuticals, Co. Ltd; Bayer; …

  • NCCN Flash Update: Ovarian Cancer Guidelines Version 3.2025 Released With Maintenance Therapy Adjustment for HR-Deficiency 18 Jul 2025 16:14 GMT

    … updates to the NCCN Drugs & Biologics Compendium. … did not receive bevacizumab (Avastin; Genentech) during primary … testing results to guide treatment selection and ensure appropriate … successful implementation of updated treatment strategies, such as …

  • New Glioma Guidelines Incorporate WHO Reclassification 18 Jul 2025 11:49 GMT

    … of high-quality clinical trials that have been done, … only been one randomized trial, which compared Avastin [bevacizumab], which … Research and Treatment of Cancer, the LEGATO trial, that is … Elekta GT Medical Tech (consultant) and Icotec Medical (honoraria, …

  • Dr Finn on Tiragolumab Plus Atezolizumab and Bevacizumab in HCC 17 Jul 2025 22:28 GMT

    … in the Department of Medicine, Division of Hematology… trial (NCT04524871) of tiragolumab in combination with atezolizumab (Tecentriq) and bevacizumab (Avastin … ) for the treatment of patients with … approved by the FDA for 5 years …

  • Dr Eng on Real-World Outcomes in US Patients With KRAS G12C–Mutated CRC 17 Jul 2025 03:39 GMT

    … Chair in Surgical and Medical Oncology, coleader of the … and a professor of medicine in Hematology and Oncology … chemotherapy with or without bevacizumab (Avastin) in the United States … using the Flatiron Foundation Medicine Clinico-Genomic database. Of …

Satisfied with the content?

Continue to create your account.